Real-World Effectiveness of Mavacamten in Canada

Bristol-Myers Squibb115 enrolled

Overview

The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.

Study Type

OBSERVATIONAL

Enrollment

115

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

MavacamtenDRUG

As detailed in the product label

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who have initiated mavacamten, as part of routine clinical care, through the Bristol Myers Squibb CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) * Adult patient (≥18 years of age or as defined per local province/territory) at Index Date (first prescribed dose of mavacamten). * Patient has been diagnosed with symptomatic oHCM of New York Heart Association (NYHA) class II to III at the time of mavacamten initiation. Exclusion Criteria: * In the 6 weeks prior to baseline (i.e., Index Date; date of first prescribed dose of mavacamten), patient has received any cardiac myosin inhibitor (including mavacamten) for oHCM or any other medical condition as part of a clinical trial.

Locations (1)

London Health Science Centre (LHSC)

London, Ontario, Canada

Outcomes

Primary Outcomes

Change in New York Heart Association (NYHA) functional class following mavacamten treatment initiation

* Proportion of patients in each New York Heart Association (NYHA) functional class following mavacamten treatment initiation * Proportion of patients with a reduction of ≥1 New York Heart Association (NYHA) functional class following mavacamten treatment initiation

Time frame: Up to 1.5 years

Secondary Outcomes

Change in left ventricular outflow tract (LVOT) with Valsalva maneuver (vLVOT) gradient following mavacamten treatment initiation

Time frame: Up to 1.5 years

Proportion of patients with left ventricular outflow tract (LVOT) with Valsalva maneuver gradient (vLVOT) < 20mmHg following mavacamten treatment initiation

Time frame: Up to 1.5 years

Age

Time frame: Baseline

Sex at birth

Time frame: Baseline

Ethnicity

Time frame: Baseline

Employment status

Time frame: Baseline

Body mass index (BMI)

Time frame: Baseline

Obstructive hypertrophic cardiomyopathy (oHCM) disease duration

Time frame: Baseline

Proportion of patients in each New York Heart Association (NYHA) functional class II and III

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.